Headache, Tension-Type

Also known as: Tension-type Headache / Tension-Type Headaches / Tension headache / Headache tension / Tension-type headache, unspecified / Tension headaches

DrugDrug NameDrug Description
DB00321AmitriptylineAmitriptyline hydrochloride, also known as _Elavil_, is a tricyclic antidepressant (TCA) with analgesic properties, widely used to treat depression and neuropathic pain [A174658]. It was originally approved by the FDA in 1977 and manufactured by Sandoz [L5308].
DB00241ButalbitalButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia [A177754]. Butalbital has a low degree of selectivity and a narrow therapeutic index [A177754]. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. As with other barbiturates, butalbital carries a risk of abuse or misuse potential, intoxication, hangover, tolerance, dependence, and overdosage possibly leading to death [FDA Label]. Butalbitalā€containing analgesics can also produce a drugā€induced headache in addition to tolerance and dependence. Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully monitored [A177754].
DB00370MirtazapineMirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.[A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]
DrugDrug NameTargetType
DB00321AmitriptylineSodium-dependent serotonin transportertarget
DB00321AmitriptylineSodium-dependent noradrenaline transportertarget
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 2target
DB00321AmitriptylineAlpha-2A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 1A2enzyme
DB00321AmitriptylineCytochrome P450 2C19enzyme
DB00321AmitriptylineCytochrome P450 2D6enzyme
DB00321AmitriptylineSerum albumincarrier
DB00321AmitriptylineAlpha-1-acid glycoprotein 1carrier
DB00321AmitriptylineHistamine H1 receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 2Atarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Atarget
DB00321AmitriptylineAlpha-1A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 3A4enzyme
DB00321AmitriptylineCytochrome P450 3A5enzyme
DB00321AmitriptylinePotassium voltage-gated channel subfamily A member 1target
DB00321AmitriptylineAlpha-1D adrenergic receptortarget
DB00321AmitriptylineDelta-type opioid receptortarget
DB00321AmitriptylineKappa-type opioid receptortarget
DB00321AmitriptylineHigh affinity nerve growth factor receptortarget
DB00321AmitriptylineBDNF/NT-3 growth factors receptortarget
DB00321AmitriptylineCytochrome P450 2C9enzyme
DB00321AmitriptylineCytochrome P450 2B6enzyme
DB00321AmitriptylineCytochrome P450 2C8enzyme
DB00321AmitriptylineHistamine H2 receptortarget
DB00321AmitriptylineHistamine H4 receptortarget
DB00321AmitriptylineSigma non-opioid intracellular receptor 1target
DB00321Amitriptyline5-hydroxytryptamine receptor 2Ctarget
DB00321AmitriptylineAlpha-1B adrenergic receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 7target
DB00321Amitriptyline5-hydroxytryptamine receptor 1Dtarget
DB00321AmitriptylineMu-type opioid receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Btarget
DB00321Amitriptyline5-hydroxytryptamine receptor 6target
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 3target
DB00321AmitriptylineUDP-glucuronosyltransferase 1-1enzyme
DB00321Amitriptyline5-hydroxytryptamine receptor 1Ctarget
DB00321AmitriptylineMuscarinic acetylcholine receptortarget
DB00321AmitriptylineHERG human cardiac K+ channeltarget
DB00321AmitriptylineMultidrug resistance protein 1transporter
DB00241ButalbitalGamma-aminobutyric acid receptor subunit alpha-1target
DB00241ButalbitalGamma-aminobutyric acid receptor subunit alpha-2target
DB00241ButalbitalGamma-aminobutyric acid receptor subunit alpha-3target
DB00241ButalbitalGamma-aminobutyric acid receptor subunit alpha-4target
DB00241ButalbitalGamma-aminobutyric acid receptor subunit alpha-5target
DB00241ButalbitalGamma-aminobutyric acid receptor subunit alpha-6target
DB00241ButalbitalNeuronal acetylcholine receptor subunit alpha-4target
DB00241ButalbitalNeuronal acetylcholine receptor subunit alpha-7target
DB00241ButalbitalGlutamate receptor 2target
DB00241ButalbitalGlutamate receptor ionotropic, kainate 2target
DB00241ButalbitalGABA-A receptor (anion channel)target
DB00370Mirtazapine5-hydroxytryptamine receptor 2Atarget
DB00370Mirtazapine5HT3 serotonin receptortarget
DB00370MirtazapineAlpha-2A adrenergic receptortarget
DB00370Mirtazapine5-hydroxytryptamine receptor 2Ctarget
DB00370MirtazapineKappa-type opioid receptortarget
DB00370MirtazapineHistamine H1 receptortarget
DB00370MirtazapineCytochrome P450 1A2enzyme
DB00370MirtazapineCytochrome P450 3A4enzyme
DB00370MirtazapineCytochrome P450 2D6enzyme
DB00370MirtazapineAlpha-1 adrenergic receptorstarget
DB00370MirtazapineSodium-dependent serotonin transportertransporter
DrugDrug NamePhaseStatusCount
DB00945Acetylsalicylic acid4Completed1
DB00321AmitriptylineNot AvailableCompleted1